Drug Trial Radar · NCT03260491
U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
312
Actual
Start
Oct 30, 2017
Primary completion
Dec 1, 2025
Study completion Jul 30, 2027
Sponsor
- Lead sponsor
- Daiichi SankyoDaiichi Sankyo (DSNKY)
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Aug 24, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study was designed to evaluate safety and antitumor activity of HER3-DXd in two parts: Dose Escalation and Dose Expansion. In Dose Escalation, HER3-DXd was evaluated in participants with metastatic or unresectable NSCLC with epidermal growth factor receptor (EGFR) activating mutation after disease progression during/after EGFR tyrosine kinase inhibitor (TKI) therapy. In Dose Expansion, HER3-DXd will be evaluated in participants with metastatic or unresectable NSCLC with EGFR activating mutation or squamous or non-squamous NSCLC (ie, without EGFR-activating mutations) with disease progression during/after systemic treatment for locally advanced or metastatic disease. In addition, HER3-DXd will be evaluated in participants with locally advanced or metastatic NSCLC whose tumors harbor a KRAS-G12C mutation after progression on the most recent line of therapy (Cohort 5).
Conditions
- Non-Small Cell Lung Cancer (NSCLC)
Interventions
HER3-DXd (FL-DP)Drug
HER3-DXd (frozen liquid drug product) consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a).
HER3-DXd (CTM-1 Lyo-DP)Drug
HER3-DXd (lyophilized drug product) consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a) that was manufactured by the clinical manufacturing sites.
HER3-DXd (CTM-3 Lyo-DP)Drug
HER3-DXd (lyophilized drug product) consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a) that was manufactured by the commercial manufacturing sites.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicities (DLTs) during dose escalationTime frame: 21 days of Cycle 1
- Summary of adverse events during dose escalationTime frame: By the global end of trial date, approximately within 36 months
- Overall response rate (ORR) assessed by Blinded Independent Central Review (BICR) Committee during dose expansion (Dose Expansion Cohorts 1, 2, 3a, 3b, and Cohort 5)Time frame: Approximately within 36 months
- Maximum serum concentration (Cmax) of HER3-DXd, total anti-HER3 antibody, and MAAA-1181a during dose expansion (Cohort 4)Time frame: During the first 5 cycles (each cycle is 21 days), including an intensive sampling schedule: pre-dose, end of infusion (EOI), 2 hour (hr), 4 hr, 8 hr post infusion, Day 8, and Day 15.
- Area under the serum concentration-time curve from time 0 extrapolated to infinity (AUCinf) and up to last quantifiable time (AUC[last]) of HER3-DXd, total anti-HER3 antibody, and MAAA-1181a during dose expansion (Cohort 4)Time frame: During the first 5 cycles (each cycle is 21 days), including an intensive sampling schedule: pre-dose, end of infusion (EOI), 2 hour (hr), 4 hr, 8 hr post infusion, Day 8, and Day 15.
Locations
37 sites in 6 countries. Site status is shown where the registry gives one.
City of Hope
Duarte, California
University of California San Diego
La Jolla, California
Pacific Shores Medical Group
Long Beach, California
Winship Cancer Institute of Emory University
Atlanta, Georgia
Massachusetts General Hospital
Boston, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts
Karmanos Cancer Institute
Detroit, Michigan
Henry Ford Hospital
Detroit, Michigan
NYU Langone Health - NYU Medical Oncology Associates
New York, New York
Memorial Sloan-Kettering Cancer Center
New York, New York
Gabrail Cancer Center (GCC) - Canton Facility
Canton, Ohio
University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center (University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania
Sarah Cannon Research Institute/Tennesse Oncology
Nashville, Tennessee
Oncology Consultants P.A.
Houston, Texas
Fred Hutchinson Cancer Center
Seattle, Washington
Northwest Medical Specialties
Tacoma, Washington
National Cancer Center Hospital East (NCCHE) - Kashiwa Campus
Kashiwa-Shi, Japan
Kurume University - Kurume University Hospital - Respiratory Diseases Center
Kurume-Shi, Japan
Kindai University Hospital
Osaka, Japan
Shizuoka Cancer Center
Shizuoka, Japan
The Cancer Institute Hospital of Japanese Foundation for Cancer Research (JFCR)
Tokyo, Japan
Netherlands Cancer Institute
Amsterdam, Netherlands
Seoul National University Hospital
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
NEXT Oncology - Hospital Quironsalud Barcelona
Barcelona, Spain
Hospital Universitario Vall d'Hebron
Barcelona, Spain
Hospital General Universitario Gregorio Maranon (HGUGM)
Madrid, Spain
Clinica Universidad Navarra(Madrid)
Madrid, Spain
Hospital Ramón y Cajal
Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Hospital Universitario Madrid Sanchinarro - Centro Integral Oncologico Clara Campal (CIOCC)
Madrid, Spain
Hospital Universitario Quirónsalud Madrid
Madrid, Spain
Clínica Universidad de Navarra (Pamplona)
Pamplona, Spain
Chung Shan Medical University Hospital
Taichung, Taiwan
National Cheng Kung University Hospital
Tainan, Taiwan
National Taiwan University Hospital
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.